Quantum Genomics SA
- Country
- 🇫🇷France
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 1
- Market Cap
- -
Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Quantum Genomics SA
- Target Recruit Count
- 419
- Registration Number
- NCT04857840
- Locations
- 🇨🇦
Canadian Phase Onward, Toronto, Ontario, Canada
🇺🇸Manassas Clinical Research Center, Manassas, Virginia, United States
Pharmacokinetics in End Stage Renal Disease Patients
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Quantum Genomics SA
- Target Recruit Count
- 28
- Registration Number
- NCT04792333
- Locations
- 🇫🇷
Eurofins Optimed, Gières, France
Firibastat in Treatment-resistant Hypertension
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Quantum Genomics SA
- Target Recruit Count
- 515
- Registration Number
- NCT04277884
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸Apex Medical Research, Chicago, Illinois, United States
🇺🇸Cedar Crosse Research Center, Chicago, Illinois, United States
Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Quantum Genomics SA
- Target Recruit Count
- 295
- Registration Number
- NCT03715998
- Locations
- 🇭🇺
Central Hospital of Hungarian Army, Budapest, Hungary
🇵🇱Krakowski Szpital Specjalistyczny im. Jana Pawła II, Kraków, Poland
🇸🇰NUSCH Bratislava Dpt. of Acute Cardiology, Bratislava, Slovakia
Evaluation of the PK Profile of Firibastat Following Administration of Firibastat Prototype Tablet Formulations
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2019-06-18
- Lead Sponsor
- Quantum Genomics SA
- Target Recruit Count
- 12
- Registration Number
- NCT03714685
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins
- First Posted Date
- 2017-06-26
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Quantum Genomics SA
- Target Recruit Count
- 256
- Registration Number
- NCT03198793
- Locations
- 🇺🇸
Progressive Medical Research, Port Orange, Florida, United States
QUantum Genomics Incremental Dosing in Heart Failure - QUID-HF
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Quantum Genomics SA
- Target Recruit Count
- 23
- Registration Number
- NCT02780180
- Locations
- 🇭🇺
Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary
🇨🇿Hospital of Fridek-Mistek P.O., Frýdek-Místek, Czechia
🇫🇷Hôpital Louis Pradel, Bron, France
Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Quantum Genomics SA
- Target Recruit Count
- 34
- Registration Number
- NCT02322450
- Locations
- 🇫🇷
Hospices Civils de Lyon - Hôpital de la Croix Rousse, Lyon, France
🇫🇷Hôpital Arthur Gardiner, Dinard, France
🇫🇷Hôpital Européen Georges Pompidou, Paris, France
Study of the Product QGC001 as a Single Dose and Multiple Doses Administered Orally to Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2013-07-16
- Lead Sponsor
- Quantum Genomics SA
- Target Recruit Count
- 69
- Registration Number
- NCT01900184
- Locations
- 🇫🇷
Biotrial PARIS, Rueil-Malmaison, France
Phase I Study in Healthy Male Subjects Comparing QGC001 to Placebo
- Conditions
- Interventions
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2013-07-16
- Lead Sponsor
- Quantum Genomics SA
- Target Recruit Count
- 56
- Registration Number
- NCT01900171
- Locations
- 🇫🇷
Biotrial PARIS, Rueil-Malmaison, France